In our ongoing commitment to better serve patients through development of innovative therapies that address unmet needs, Astellas is proud to share recent top leadership appointments across our...

Astellas was recognized in Seramount’s 2021 Top 75 Companies for Executive Women list. Seramount announced its annual list of the 2021 Top 75 Companies for Executive Women and has included...

Clinical trials are a crucial step in drug development to find out if an experimental treatment is safe and effective in treating a specific condition or disease. But clinical trials also trigger...

National Disability Employment Awareness Month is observed in the United States every October to recognize the workplace accomplishments of people living with disabilities and to reaffirm our...

The article below, co-authored by Mark Reisenauer, president of Astellas Pharma US, Tim Walbert, chairman, president and CEO of Horizon Therapeutics, and Peter Anastasiou, executive vice president...

Astellas was recently ranked in Seramount’s (formerly Working Mother Media) 2021 100 Best Companies and Best Companies for Dads lists. We recognize Carrie Schimizzi, Executive Director,...

Astellas is committed to partnering with national and local non-profit organizations to help improve access to healthcare for underserved groups in the United States. In Fiscal Year 2020, the...

Improved score marks continuing effort in growing inclusive culture to support people with disabilities For the second year in a row, Astellas has been included in the Disability Equality Index as...

Astellas, through its Mitobridge affiliate, has dosed the first patient in its pivotal Phase 2/3 clinical trial for ASP0367*, an oral investigational drug that may improve exercise intolerance and...

Astellas Pharma Inc. announced changes in its Global Commercial Leadership Team reporting to Chief Commercial Officer Yukio Matsui aligned with the focuses for the new Corporate Strategic Plan 2021 (CSP2021).